Author: Angeline Leishman|| Date Published: December 30, 2021
Merck’s life science business has been awarded a three-year, $136.7 million contract to stand up a factory for a critical material needed to manufacture rapid COVID-19 point-of-care tests.
MilliporeSigma said Thursday it will use the funds to establish a lateral flow membrane production facility in Sheboygan, Wisconsin, to support domestic production and supply efforts for the government’s pandemic preparedness initiative.
The business supplies its Hi-Flow Plus nitrocellulose membrane to manufacturers of medical test kits intended to diagnose infectious diseases such as COVID-19, malaria and HIV.
Former NASA executive Dan Tenney has been selected to succeed Michael Williamson as senior vice president of global business development and strategy at Lockheed…
bachelor’s”Brandy Durham has taken on new responsibilities as chief data and artificial intelligence officer at ManTech. The Herndon, Virginia-based company…